{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:38:19Z","timestamp":1782243499713,"version":"3.54.5"},"reference-count":52,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PRIN Progetti di Ricerca di Rilevante Interesse Nazionale 2022","award":["2022FRSS2H"],"award-info":[{"award-number":["2022FRSS2H"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The triple combination therapy for cystic fibrosis (CF), including elexacaftor, tezacaftor and ivacaftor (ETI or Trikafta), has been shown to improve lung function and reduce pulmonary exacerbations, thereby enhancing the quality of life for most CF patients. Recent findings suggest that both the individual components and ETI may have potential off-target effects, highlighting the need to understand how these modulators impact cellular physiology, particularly in cells that do not express CF transmembrane conductance regulator (CFTR). We used HEK293 cells, as a cell model not expressing the CFTR protein, to evaluate the effect of ETI and each of its components on autophagic machinery and on the Rab5\/7 components of the Rab pathway. We firstly demonstrate that the single modulators Teza and Iva, and the combinations ET and ETI, increased ROS production in the absence of their target while decreasing it in cells expressing the CFTR \u2206F508del. This increase in cellular stress was followed by an increase in the total level of polyubiquitinated proteins as well as the p62 level and LC3II\/LC3I ratio. Furthermore, we found that ETI had the opposite effect on Rabs by increasing Rab5 levels while decreasing Rab7. Interestingly, these changes were abolished by the expression of mutated CFTR. Overall, our data suggest that in the absence of their target, both the individual modulators and ETI increased ROS production and halted both autophagic flux and plasma membrane protein recycling.<\/jats:p>","DOI":"10.3390\/ijms251910360","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:55:52Z","timestamp":1727333752000},"page":"10360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of CFTR Modulators on Oxidative Stress and Autophagy in Non-CFTR-Expressing Cells"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-7315","authenticated-orcid":false,"given":"Filippo","family":"Scial\u00f2","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Napoli, Italy"},{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1370-9786","authenticated-orcid":false,"given":"Gustavo","family":"Cernera","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Napoli, Italy"},{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Polise","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Napoli, Italy"},{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castaldo","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Napoli, Italy"},{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0596-2933","authenticated-orcid":false,"given":"Felice","family":"Amato","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Napoli, Italy"},{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4858-4853","authenticated-orcid":false,"given":"Valeria Rachela","family":"Villella","sequence":"additional","affiliation":[{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"Freedman","year":"2009","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1164\/rccm.2601006","article-title":"Update in cystic fibrosis 2005","volume":"173","author":"Accurso","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/j.gastro.2010.04.004","article-title":"Dynamic regulation of CFTR bicarbonate permeability by [Cl\u2212]i and its role in pancreatic bicarbonate secretion","volume":"139","author":"Park","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1152\/physrev.1999.79.1.S3","article-title":"Physiological basis of cystic fibrosis: A historical perspective","volume":"79","author":"Quinton","year":"1999","journal-title":"Physiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.256.5058.774","article-title":"Cystic fibrosis: Molecular biology and therapeutic implications","volume":"256","author":"Collins","year":"1992","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pneumo.2014.11.008","article-title":"Therapeutic advances in cystic fibrosis in 2014","volume":"72","author":"Durupt","year":"2016","journal-title":"Rev. Pneumol. Clin."},{"key":"ref_8","unstructured":"(2024, September 23). This Patient Information Has Been Approved by the U.S. Food and Drug Administration. Revised: 08\/2023. Available online: https:\/\/pi.vrtx.com\/files\/uspi_elexacaftor_tezacaftor_ivacaftor.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_10","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20503121231225874","DOI":"10.1177\/20503121231225874","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials","volume":"12","author":"He","year":"2024","journal-title":"SAGE Open Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Robinson","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","unstructured":"(2024, September 23). A Phase 3 Study of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F\/MF), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525444."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Castaldo, A., Iacotucci, P., Bagnasco, S., Fevola, C., Carnovale, V., Antonelli, F., Cernera, G., Gelzo, M., and Terlizzi, V. (2024). Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68511-7"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Castaldo, A., Gelzo, M., Iacotucci, P., Longobardi, A., Taccetti, G., Terlizzi, V., and Carnovale, V. (2024). One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1327958"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114176","DOI":"10.1016\/j.jpeds.2024.114176","article-title":"Reported Adverse Events in a Multicenter Cohort of Patients Ages 6\u201318 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"274","author":"Terlizzi","year":"2024","journal-title":"J. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Carnovale, V., Scial\u00f2, F., Gelzo, M., Iacotucci, P., Amato, F., Zarrilli, F., Celardo, A., Castaldo, G., and Corso, G. (2022). Cystic Fibrosis Patients with F508del\/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor\/Tezacaftor\/Ivacaftor Treatment. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236900"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Piona, C., Mozzillo, E., Tosco, A., Volpi, S., Rosanio, F.M., Cimbalo, C., Franzese, A., Raia, V., Zusi, C., and Emiliani, F. (2022). Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144149"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ciobanu, D.Z., Liessi, N., Tomati, V., Capurro, V., Bertozzi, S.M., Summa, M., Bertorelli, R., Loberto, N., Dobi, D., and Aureli, M. (J. Cyst. Fibros., 2024). Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS), J. Cyst. Fibros., in press.","DOI":"10.1016\/j.jcf.2024.05.004"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcf.2023.04.012","article-title":"The combination elexacaftor\/tezacaftor\/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner","volume":"22","author":"Liessi","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"00127-2017","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cigana, C., Giannella, R., Colavolpe, A., Alcal\u00e1-Franco, B., Mancini, G., Colombi, F., Bigogno, C., Bastrup, U., Bertoni, G., and Bragonzi, A. (2023). Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.04083-22"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1945892418815615","article-title":"Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity against Pseudomonas aeruginosa","volume":"33","author":"Cho","year":"2019","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"118317","DOI":"10.1016\/j.cca.2024.118317","article-title":"Identification of an ultra-rare Alu insertion in the CFTR gene: Pitfalls and challenges in genetic test interpretation","volume":"558","author":"Esposito","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1152\/physrev.00059.2009","article-title":"Role of Rab GTPases in membrane traffic and cell physiology","volume":"91","author":"Hutagalung","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Badr, A., Eltobgy, M., Krause, K., Hamilton, K., Estfanous, S., Daily, K.P., Abu Khweek, A., Hegazi, A., Anne, M.N.K., and Carafice, C. (2022). CFTR Modulators Restore Acidification of Autophago-Lysosomes and Bacterial Clearance in Cystic Fibrosis Macrophages. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.819554"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"McDonald, E.F., Kim, M., Olson, J.A., Meiler, J., and Plate, L. (2024). Proteostasis Landscapes of Selective versus Poorly Responsive CFTR Variants Reveals Structural Vulnerabilities to Correction. bioRxiv.","DOI":"10.1101\/2024.07.10.602964"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/cdd.2013.46","article-title":"Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator","volume":"20","author":"Villella","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.4161\/auto.21483","article-title":"Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on \u0394F508 cystic fibrosis transmembrane conductance regulator","volume":"8","author":"Luciani","year":"2012","journal-title":"Autophagy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/ncb2090","article-title":"Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition","volume":"12","author":"Luciani","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41419-019-1500-x","article-title":"Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis","volume":"10","author":"Villella","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kumar, A.V., Mills, J., and Lapierre, L.R. (2022). Selective Autophagy Receptor p62\/SQSTM1, a Pivotal Player in Stress and Aging. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.793328"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)","volume":"17","author":"Klionsky","year":"2021","journal-title":"Autophagy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/21541248.2017.1317700","article-title":"Rab GTPases regulate the trafficking of channels and transporters\u2014A focus on cystic fibrosis","volume":"9","author":"Farinha","year":"2018","journal-title":"Small GTPases"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2016.04.001","article-title":"Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling","volume":"100","author":"Brand","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_39","first-page":"1225578","article-title":"ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways","volume":"2022","author":"Dantas","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_44","unstructured":"(2024, September 23). Available online: www.trikafta.com\/safety-side-effects."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rachel, M., Galiniak, S., Biesiadecki, M., and Gala-B\u0142\u0105dzi\u0144ska, A. (2022). Renal Function in Patients with Cystic Fibrosis: A Single-Center Study. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19095454"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcf.2013.03.005","article-title":"A review of renal disease in cystic fibrosis","volume":"12","author":"Nazareth","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","article-title":"Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100270","DOI":"10.1016\/j.jlr.2022.100270","article-title":"Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro","volume":"63","author":"Zarini","year":"2022","journal-title":"J. Lipid Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.116.305675","article-title":"Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation","volume":"36","author":"Edsfeldt","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:03:41Z","timestamp":1760112221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":52,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910360"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910360","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}